Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481830 · ClinicalTrials.gov registry record · Phase 3
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 569
- Enrollment target
NCT02481830: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT02481830 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 569 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02481830, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 569 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
Primary Outcome
The time from randomization to the date of death, data was based on Kaplan-Meier Estimates. A participant who has not died will be censored at last known date alive.
Interventions
- DRUG Nivolumab
- DRUG Topotecan
- DRUG Amrubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 569 participants |
| Start Date | 2015-09-14 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 3 |
What the finished NCT02481830 record still lists
NCT02481830 is an interventional study that assigns participants to a tested intervention. The registered 569 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02481830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02481830 about?
NCT02481830 is a clinical study titled "Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer". The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
What is the current status of trial NCT02481830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 569 participants. The study started on 2015-09-14. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT02481830?
The interventions under investigation include: Nivolumab (DRUG), Topotecan (DRUG), Amrubicin (DRUG).
Who is sponsoring clinical trial NCT02481830?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02481830's enrollment target sits among peer trials
569 666th of 2000 higher than 1,335 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000645 · 570 participants · NA
Grocery Delivery and Healthy Weight Gain Among Low-income Pregnant Young Women
- NCT06239844 · 570 participants · NA
Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English
- NCT06701903 · 570 participants · Phase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
- NCT07266831 · 570 participants · Phase 2
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI